Ultrasound-guided Continuous Low Serratus Anterior Plane Block in Hepatocellular Carcinoma Surgery
Launched by LIU DI · Sep 3, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new method to help manage pain for patients undergoing surgery for liver cancer, specifically a type called hepatocellular carcinoma. The researchers want to see if using an ultrasound-guided technique to deliver continuous pain relief through a specific area near the ribs (called the serratus anterior plane) can improve comfort after surgery.
To participate in this trial, you need to be between 18 and 60 years old, have an average body weight for your height, and be in generally good health. Unfortunately, if you have serious heart, brain, liver, or kidney problems, certain mental health conditions, or allergies to anesthesia, you won't be eligible. Participants can expect to receive this new pain management technique during their surgery and will be monitored closely to evaluate how well it works. This trial is currently recruiting participants, and your involvement could help improve pain relief options for future patients undergoing similar surgeries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 18-60 years;
- • 2. ASAI-II;
- • 3. BMI: 18-29 kg/m2
- Exclusion Criteria:
- • 1. Combined cardiac, cerebral, hepatic, and renal failure;
- • 2. Comorbid psychiatric and neuromuscular disorders;
- • 3. A history of allergy to anesthetic drugs;
- • 4. Participation in other recent clinical or drug trials.
About Liu Di
Liu Di is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on developing groundbreaking therapies across various therapeutic areas, Liu Di collaborates with healthcare professionals and research institutions to ensure rigorous study design and ethical standards. The organization prioritizes patient safety and data integrity while striving to accelerate the delivery of effective treatments to market. Through its expertise in clinical development and regulatory compliance, Liu Di plays a pivotal role in enhancing healthcare outcomes and improving the quality of life for patients globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Neijiang, Sichuan, China
Patients applied
Trial Officials
ailing wu, Doctor
Study Director
First People's Hospital of Neijiang.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials